Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Chaumont-Gistoux – page 83

1 874 clinical trials in Chaumont-Gistoux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaumont-Gistoux at a glance
1 874
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 874 trials in Chaumont-Gistoux

Open in trial search
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Safety, Tolerability and Pharmacokinetics of Oral PF-07293893 in Healthy Adults for Future Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:PF-07293893
  • Sponsor:Pfizer Inc.

Relative Bioavailability of Sisunatovir Capsules vs Tablets in Fasted and Fed Conditions in Healthy Adults with Respiratory Syncytial Virus

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sisunatovir
  • Sponsor:Pfizer Inc.

Colitis ulcerative+4

Not recruiting

Pharmacokinetic Study of Ritlecitinib Tosilate in Healthy Adults: Oral Solution, Short‑and Long‑Duration Capsules Fed vs Fasted – for ulcerative colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Pfizer Inc.

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Overweight

Not recruiting

Study of PF-08653945 Bioavailability After Subcutaneous Injection in the Thigh, Upper Arm, or Abdomen in Adults with Obesity

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:PF-08653945
  • Sponsor:Pfizer Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Chaumont-Gistoux

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The study explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment protocols for long-term digestive health management.

02 Digestive Health Studies

Research examining the effectiveness of different management strategies for heartburn and reflux symptoms. The trials evaluate various therapeutic approaches, including alginate formulations as alternative treatments.

  • Symptom Management
  • Treatment Optimization
  • Patient-Centered Care

These investigations aim to improve quality of life for patients while identifying more targeted and efficient treatment strategies.

03 Primary Care Innovation

Forward-thinking research in primary care settings focusing on medication optimization and patient-centered approaches to chronic condition management.

  • Medication Management
  • Evidence-Based Protocols
  • Clinical Practice Enhancement

This research aims to establish better guidelines for long-term medication management in primary care practices.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.